DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keller, C.
Right arrow Articles by Enz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keller, C.
Right arrow Articles by Enz, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PYRROLE

Vol. 30, Issue 2, 173-176, February 2002

Brain Pharmacokinetics of a Nonpeptidic Corticotropin-Releasing Factor Receptor Antagonist

Caroline Keller, Armin Bruelisauer, Michel Lemaire, and Albert Enz

Novartis Pharma AG, Basel, Switzerland

Corticotropin-releasing factor (CRF) is known to play an important role in the body response to stress. Butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine (CP-154,526) is a CRF1 antagonist showing anxiolytic activities in rats in behavioral models, suggesting that CP-154,526 crosses the blood-brain barrier. However, there is no direct evidence for this. This study determined the pharmacokinetic profile of CP-154,526 in rats after i.v. and p.o. application. After i.v. bolus, the concentration declined in a biphasic manner, the first half-life being 0.9 h and the terminal one being 51 h. Systemic clearance was 36 ml/min/kg, and the volume of distribution was 105 l/kg. Oral bioavailability reached 27%. To study brain pharmacokinetics, rats were given a single dose of CP-154,526 p.o. or i.v. and sacrificed after different post-treatment times. Plasma, cortex, striatum, hypothalamus, hippocampus, and cerebellum concentrations were measured. After i.v. bolus, maximal brain concentration was reached after 20 min. The hypothalamus displayed significantly lower concentrations compared with the other brain tissues. In the p.o. study, the maximal plasma concentration was reached after 30 min, whereas the maximal brain concentration was observed after 1 h and remained stable until 2 h post-treatment, without significant differences between the brain tissues. The unidirectional brain extraction ratio was 27 and 9% at vascular concentrations of 0.08 and 16 nmol/ml, respectively. These results demonstrate a large brain penetration of CP-154,526 after i.v. and p.o. applications and a comparable distribution among the brain regions, except for the hypothalamus, which displayed lower concentrations after i.v. bolus.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Larauche, G. Gourcerol, L. Wang, K. Pambukchian, S. Brunnhuber, D. W. Adelson, J. Rivier, M. Million, and Y. Tache
Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways
Am J Physiol Gastrointest Liver Physiol, July 1, 2009; 297(1): G215 - G227.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Larauche, S. Bradesi, M. Million, P. McLean, Y. Tache, E. A. Mayer, and J. A. McRoberts
Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats
Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G1033 - G1040.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. R. Gehlert, A. Cippitelli, A. Thorsell, A. D. Le, P. A. Hipskind, C. Hamdouchi, J. Lu, E. J. Hembre, J. Cramer, M. Song, et al.
3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism
J. Neurosci., March 7, 2007; 27(10): 2718 - 2726.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. Porcher, A. Juhem, A. Peinnequin, V. Sinniger, and B. Bonaz
Expression and effects of metabotropic CRF1 and CRF2 receptors in rat small intestine
Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G1091 - G1103.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
I. Schwetz, S. Bradesi, J. A. McRoberts, M. Sablad, J. C. Miller, H. Zhou, G. Ohning, and E. A. Mayer
Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors
Am J Physiol Gastrointest Liver Physiol, April 1, 2004; 286(4): G683 - G691.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Zhang, N. Huang, Y.-W. Li, X. Qi, A. P. Marshall, X.-X. Yan, G. Hill, C. Rominger, S. R. Prakash, R. Bakthavatchalam, et al.
Pharmacological Characterization of a Novel Nonpeptide Antagonist Radioligand, ({+/-})-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for Corticotropin-Releasing Factor1 Receptors
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 57 - 69.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y.-W. Li, G. Hill, H. Wong, N. Kelly, K. Ward, M. Pierdomenico, S. Ren, P. Gilligan, S. Grossman, G. Trainor, et al.
Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 86 - 96.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.